Trials / Completed
CompletedNCT02139397
Study of Difluoromethylornithine (DFMO) in Combination With Bortezomib for Relapsed or Refractory Neuroblastoma
A Phase I/II Trial of DFMO in Combination With Bortezomib in Patients With Relapsed or Refractory Neuroblastoma
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Giselle Sholler · Academic / Other
- Sex
- All
- Age
- 21 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research study is to evaluate an investigational drug (DFMO) in combination with bortezomib, for relapsed and refractory neuroblastoma. DFMO is an investigational drug because it has not been approved by the U.S. Food and Drug Administration (FDA). This study will look at the safety and tolerability of DFMO in combination with bortezomib as well as the tumors response to this study drug.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DFMO | |
| DRUG | Bortezomib |
Timeline
- Start date
- 2014-06-06
- Primary completion
- 2024-01-19
- Completion
- 2024-01-19
- First posted
- 2014-05-15
- Last updated
- 2024-08-06
- Results posted
- 2024-04-25
Locations
6 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02139397. Inclusion in this directory is not an endorsement.